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Abstract
Background: Aberrations in the Wnt pathway have been reported to be involved in the metastasis of prostate cancer 
(PCa) to bone. We investigated the effect and underlying mechanism of a naturally-occurring Wnt inhibitor, WIF1, on 
the growth and cellular invasiveness of a bone metastatic PCa cell line, PC3.
Results: The WIF1 gene promoter was hypermethylated and its expression down-regulated in the majority (7 of 8) of 
PCa cell lines. Restoration of WIF1 expression in PC-3 cells resulted in a decreased cell motility and invasiveness via up-
regulation of epithelial markers (E-cadherin, Keratin-8 and-18), down-regulation of mesenchymal markers (N-cadherin, 
Fibronectin and Vimentin) and decreased activity of MMP-2 and -9. PC3 cells transfected with WIF1 consistently 
demonstrated reduced expression of Epithelial-to-Mesenchymal Transition (EMT) transcription factors, Slug and Twist, 
and a change in morphology from mesenchymal to epithelial. Moreover, WIF1 expression significantly reduced tumor 
growth by approximately 63% in a xenograft mouse model. This was accompanied by an increased expression of E-
cadherin and Keratin-18 and a decreased expression of vimentin in tumor tissues.
Conclusion: These data suggest that WIF1 regulates tumor invasion through EMT process and thus, may play an 
important role in controlling metastatic disease in PCa patients. Blocking Wnt signaling in PCa by WIF1 may represent a 
novel strategy in the future to reduce metastatic disease burden in PCa patients.
Introduction
Prostate cancer (PCa) is the second most frequent cause
of cancer-related mortality in men in the United States
[1,2]. Although a significant portion of PCa is curable
either by surgery or by radiotherapy when detected early
[1,2], advanced PCa with metastases still presents a diffi-
cult therapeutic problem. Specifically, bone metastasis is
the major cause of mortality in patients with PCa. There-
fore, understanding the processes that promote metasta-
sis of PCa could be useful in designing effective therapies
for advanced PCa with bone metastasis.
The wingless-type (Wnt) pathway plays a central role in
the development of many tissues and organisms. Aber-
rant activation of the Wnt pathway contributes to the
progression of several major human cancers, including
PCa [3,4]. The best-studied Wnt signaling pathway is the
Wnt/β-catenin pathway, comprised of secreted Wnt
ligands and cell-surface receptors called Frizzled and
Lipoprotein Receptor-Related Protein 5/6 (LRP5/6) [3,4].
In the presence of ligandreceptor binding, cytosolic β-
catenin is translocated into the nucleus, and forms a com-
plex with TCF family of transcription factors to activate
target genes [3,4]. In contrast, Wnt inhibition leads to
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decreased accumulation of cytosolic and nuclear β-
catenin with consequent downregulation of Wnt-respon-
sive genes [3,4]. An exhaustive list of Wnt target genes
has been posted in "The Wnt homepage" website, which
includes cell cycle regulators, metalloproteinase (MMP),
CD44, Met, Jagged1, vascular endothelial growth factor,
etc. [5]. This list indicates that the Wnt pathway partici-
pates in not only cell proliferation, but also cell invasion,
metastasis and angiogenesis through regulation of Wnt
target gene expression in a context-dependent fashion.
In addition to Wnt ligands and receptors, three classes
of secreted antagonists of the Wnt pathway have been
identified: secreted Frizzled-related protein (sFRP) fam-
ily, Dickkopf (Dkk) family, and Wnt inhibitory factor 1
(WIF1) [6-9]. These antagonists can modulate Wnt sig-
naling either by binding to Wnt ligands or by binding to
the LRP5/6 co-receptor, leading to receptor endocytosis
[6-9]. Initially, it was thought that activating mutations of
APC or β-catenin were the dominant mechanisms of Wnt
activation in cancer [10]. However, recent evidence shows
that secreted Wnt antagonists (e.g. sFRP1) can suppress
Wnt signaling despite the presence of these down-stream
activating mutations, suggesting autocrine Wnt signaling
could be involved in cancer progression [11,12]. More-
over, emerging evidence demonstrates that PCa tissues
and cell lines, as well as stromal components of the pros-
tate express Wnt ligands and receptors, thus implicating
autocrine or paracrine signaling in at least a subset of
prostate tumors [13-16]. As such, the use of secreted
antagonists to suppress autocrine and/or paracrine Wnt
signaling and its downstream targets in PCa may be a via-
ble option for reduction of tumor burdens.
WIF1 silencing by hypermethylation and consequent
Wnt signaling activation has been demonstrated in
numerous cancers such as nasopharyngeal cancer [17],
lung cancer [18], mesothelioma [19], breast cancer [20],
urinary bladder cancer [21], renal cancer [22], osteosar-
coma [23,24] and gastric cancer [25]. Compared to other
secreted Wnt antagonists, WIF1 has been consistently
shown to inhibit the in vitro and in vivo growth of various
cancer cells [26,27]. WIF1 is down-regulated in 64% (27
of 42) of primary PCa specimens [26] and overexpression
of WIF1 in PC3 cells increases the efficacy of Paclitaxel to
induce apoptosis [27]. However, the mechanism of WIF1
down-regulation and the function roles of WIF1 expres-
sion in PCa remain unknown.
In addition, WIF1 has been implicated to play a role in
normal prostate development [28,29]. In a study on early
androgen induced prostate development, nearly all Wnts,
along with WIF1 were expressed in the developing pros-
tate, suggesting Wnt signaling as one of the major andro-
gen regulated pathways in early prostate development
[28]. In a tissue recombination experiment for studying
induction of prostate formation, the overexpression of
WIF1 in urogenital sinus mesenchyme inhibited prostate
formation [29]. Furthermore, WIF1 was shown to be
highly expressed in the developing and mature mouse
skeleton and involved in osteoblast differentiation and
chondrogenesis [30,31]. Targeted deletion of mouse
WIF1 augmented spontaneous and radiation-induced
osteosarcoma formation [23]. Together, these studies sug-
gested that WIF1 plays an important functional role in
both the prostate and bone (the most common metastasis
site of PCa). Therefore, further investigation is warranted
regarding WIF1 down regulation in PCa and the potential
of WIF1 as a future target for novel therapies.
In this report, WIF1 expression was down-regulated in
the majority of PCa cell lines via promoter hypermethyla-
tion. Ectopic expression of WIF1 in a bone-metastatic
PCa cell line PC-3 resulted in up-regulation of epithelial
markers (E-cadherin, Keratin-8 and-18) and down-regu-
lation of mesenchymal makers (N-cadherin, Fibronectin
and Vimentin) both in vivo and  in vitro, suggesting a
reversal of EMT. Moreover, WIF1 expression resulted in
decreased cell motility and invasiveness in cell cultures,
as well as reduced tumor growth in a PCa xenograft
model.
Materials and methods
Plasmids, cell lines and stable transfection
PC3, 22Rv1, LNCaP and DU145 cells were obtained from
American Type Culture Collection (Manassas, VA) and
maintained in RPMI 1640 supplemented with 10% fetal
bovine serum (FBS) and antibiotics. C4-2B (ViroMed
Laboratories; Minneapolis, MN), an LNCaP subline, was
grown in RPMI 1640 supplemented with 5% FBS. LAPC-
4 (a gift from Dr. C. Sawyer) cells were cultured in RPMI
1640 supplemented with 10% FBS. PC3 M and PC3M-
LN4 Cells were kindly provided by Dr . Curtis Pettaway
(M. D. Anderson Cancer Center, Houston, TX) and were
cultured in RPMI medium containing 10% FBS. Primary
prostate epithelial cells (PrEC) came from Cambrex Bio-
science (Walkersville, MD) and were grown in prostate
epithelial basal medium. PCDNA3.1 Directional TOPO
Expression vector was obtained from Invitrogen. An Ulti-
mate ORF WIF1  clone (ID: IOH11153) was obtained
from Invitrogen, subcloned into the PCDNA3.1 TOPO
vector containing a V5 tag and verified by automated
DNA sequencing using standard methods. For stable
transfection, PC3 cells were plated at 1.6 × 105 per 100-
mm dish. At 60% confluency, cultures were transfected
with  PCDNA3.1 or WIF1 using FuGENE 6 (Roche)
according to manufacturer's instruction. After transfec-
tion, stable clones were selected with G418 (800 μg/ml)
starting at 48 h post transfection and assayed for expres-
sion of the transgene by western blot and real-time RT-Yee et al. Molecular Cancer 2010, 9:162
http://www.molecular-cancer.com/content/9/1/162
Page 3 of 14
PCR. Pooled transfectants (to avoid cloning artifacts) are
propagated and maintained in RPMI 1640 containing
10% FBS and 500 μg/mL G418.
Luciferase and β-galactosidase assays
PC3 cells stably expressing PCDNA3.1  or  WIF1  were
grown in six-well plates and transiently cotransfected
with 1 μg pTOPFLASH or pFOPFLASH and 0.1 μg cyto-
megalovirus (CMV)-β-galactosidase plasmids (Invitro-
gen, Carlsbad, CA) using FuGENE 6. After 24 hours of
incubation, cells were harvested and the luciferase and β-
galactosidase activities were measured using Bright-Glo
luciferase assay system and β-galactosidase enzyme assay
system (Promega, Madison, WI). The relative luciferase
unit for each transfection was adjusted by β-galactosidase
activity in the same sample.
Protein extraction, conditioned medium, and Western 
blotting
For extraction of membrane and cytosolic proteins [32],
cells were collected in TES suspension buffer and homog-
enized on ice. The cytosolic fraction was recovered by
ultracentrifugation at 100,000 × g. The membrane-
enriched pellet was solubilized in solubilization buffer.
For extraction of total proteins, cells were lysed in radio-
immunoprecipitation assay buffer. Conditioned media
were prepared using serum-free RPMI by culturing PC3
cells stably transfected with vector control or WIF1 at
70% confluence for 48 hours and concentrated 40 times
by Centricon (Millipore, Bedford, MA). Clarified protein
lysates (20-80 μg) or concentrated conditioned medium
were electrophoretically resolved on denaturing SDS-
polyacrylamide gel (8-16%), transferred to nitrocellulose
membranes, and probed with antibodies against β-
catenin (Upstate Biotechnology, Charlottesville, VA), E-
cadherin and N-cadherin (BD Biosciences, San Diego,
CA), keratin-8, keratin-18, fibronectin, and vimentin (Lab
Vision, Fremont, CA), Phospho-AKT, AKT, GSK-3β and
phospho-GSK-3β (Cell Signaling, Beverly, MA), c-myc
(Calbiochem, San Diego, CA), cyclin D1, Slug, Twist,
WIF1, and β-actin (Santa Cruz Biotechnology, Santa
Cruz, CA). Proteins were revealed using secondary anti-
bodies and visualized by an enhanced chemilumines-
cence detection system (Amersham Bioscience,
Piscataway, NJ).
Immunocytofluorescence assay
Cells were cultured in chamber slides (Lab-Tek). After
methanol fixation and permeabilization with Triton X-
100, cells were incubated with an anti-E-cadherin anti-
body (BD Biosciences) and then with an Alexa 488-conju-
gated secondary antibody (Molecular Probes, Inc.,
Eugene, OR). Localization of E-cadherin was analyzed
under confocal microscopy (Zeiss, Thornwood, NY)
using the 488 nm excitation wavelengths of the laser.
RT-PCR and RT-real time-PCR
Total RNA was isolated from PC3, 22Rv1, LNCaP, C4-2B,
PrEC, LAPC-4, PC3 M, PC3M-LN4, DU145, PcDNA3.1/
PC-3 and WIF1/PC-3 cells using the RNAazol B method
as described [33]. RNA was treated with ribonuclease-
free DNaseI to remove any contaminating DNA. Reverse
transcription of 1 μg total RNA was performed using the
Reverse Transcription System (Promega) with oligo-dT
primers. Real-time RT-PCR was performed as previously
described [32] using a MyiQ real-time thermocycler (Bio-
Rad). The PCR condition was as follows: 95°C for 5 min-
utes, 40 cycles of 30 seconds at 95°C, 30 seconds at 68°C,
60 seconds at 72°C. Relative quantitative fold change
compared to control was calculated using the compara-
t i v e  C t  m e t h od  [ 3 2 ] .  D a t a  w e r e  a n a l yz e d  b y  u s i n g  t h e
comparative Ct method [32], where Ct is the cycle num-
ber at which fluorescence first exceeds the threshold. The
Ct values from each sample were obtained by subtracting
the values for β-actin  Ct from the WIF1, E-cadherin,
Twist, or Slug Ct value. The variation of β-actin Ct values
is <0.5 among different samples. One difference of Ct
value represents a 2-fold difference in the level of mRNA.
Specificity of resulting PCR products was confirmed by
melting curves. Ct is the cycle number at which fluores-
cence intensity first exceeds the threshold level. Δ Ct is Ct
(target gene) - Ct  (actin). Gene specific primer pairs
(including product size) are available upon request. Spec-
ificity of amplification products were checked by melting
curve analysis and agarose gel electrophoresis.
Matrigel invasion assay
To assay cell motility, 2.5 × 104 cells per well in serum-free
RPMI were placed in the upper chamber. RPMI plus 10%
FBS was placed in the lower chamber as a source of
chemoattractant. Cells were allowed to migrate through a
porous, uncoated membrane (BD Biosciences) for 24
hours at 37°C. Nonmigratory cells in the upper chamber
then were removed with a cotton-tip applicator. Migrated
cells on the lower surface were fixed with methanol and
stained with hematoxylin. The number of migrating cells
was determined by counting 10 high-power fields (×100)
on each membrane and calculated as mean number of
cells per field. For invasion assays, 24-well invasion cham-
ber system (BD Biosciences) was used. Viable cells (2.5 ×
104/well) in serum-free RPMI were seeded in the upper
chamber coated with Matrigel. RPMI plus 10% FBS was
placed in the bottom well. Incubation was carried out for
48 hours at 37°C. The membrane was processed as
described for the motility assay. An invasion index, cor-
rected for cell motility, was calculated as follows:
No. of cells invaded through a Matrigel coated membrane
No.
−
   of cells migrated through an uncoated  control  membrane ()
× ×100Yee et al. Molecular Cancer 2010, 9:162
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All of the cell lines were assayed in triplicate for each
experiment, and each experiment was repeated thrice.
Gelatin zymography
Samples were applied to nondenaturing 10% polyacryl-
amide gels containing 1 mg/mL gelatin. After electropho-
resis, the gels were washed with 2.5% Triton X-100,
incubated overnight at 37°C in zymography buffer, and
stained with Coomassie brilliant blue. Gelatinolytic activ-
ity was visualized as clear areas of lysis in the gel.
Motility assay
Motility was assessed with a scratch assay to measure
two-dimensional cellular movement. PcDNA3.1  vector
control and WIF1-transfected PC3 cells were cultured to
confluence in 24-well plates. A scratch was made on the
monolayer using a sterile pipette tip. The monolayer was
washed with migration assay buffer consisting of serum-
free medium plus 0.1% BSA. At the initiation of the
experiment, a digital image of the scratch wound was
taken at 10× magnification. At 30 hours, the same region
was imaged again. The width of the scratch wounds was
m e a s u r e d  i n  P h o t o s h o p 7 . 0  ( A d o b e ) .  T h e  r e l a t i v e  f o l d
change of the scratch wound width (%) at 30 hour after
introduction of the scratch wound compared to the con-
trol was calculated as the average of 5 fields (40× magnifi-
cation).
Methylation studies
Genomic DNA was obtained from PCa cell lines includ-
ing PC3, 22Rv1, LNCaP, C4-2B, LAPC-4, PC3 M, PC3M-
LN4, and DU145 as well as from PrEC cells using Blood &
cell culture DNA mini kit (Qiagen). In order to quantify
DNA methylation, the EZ DNA Methylation-Gold Kit
(Zymo Research) was used. Briefly, 20 μl (2 μg) of
genomic DNA was diluted in C to T conversion reagent
(bisulfite). The DNA was denatured and converted at
98°C for 10 minutes and 64°C for 2.5 hours. Bisulfite-
treated DNA was then cleaned and desulphonated using
the M-binding buffer, followed by wash buffer, and desul-
phonation buffer. The bisulfite modified DNA was ampli-
fied by PCR using a pair of methylation specific primers
(MSP, forward: 5'-GGGCGTTTTATTGGGCG TAT-3'£»
reverse: 5'-AAACCAACAATCAACGAAC-3') and un-
methylation specific primers (UMSP, forward: 5'GGGT-
GTTTTATTGGGTGTAT-3'; reverse: 5'-AAACCAA-
CAATCAACAAAAC-3).
In vivo tumor model
N C R - n u / n u  ( n u d e )  m i c e  w e r e  o b t a i n e d  f r o m  T a c o n i c
(Germantown, NY). Cells from each stable line were con-
centrated to 2 × 106 per 200 μL and injected s.c. into the
left flank of each mouse. Once xenografts became estab-
lished, their sizes were measured every 3 days. The tumor
volume was calculated by the formula: 0.5236L1(L2)2,
where L1 is the long axis and L2 is the short axis of the
tumor. All of the animal studies were approved by the
Institutional Animal Care and Use Committee at Univer-
sity of California (Irvine, CA).
Immunohistochemistry
Tumor tissue slides were de-paraffinized and dehydrated
using Slide Brite (Sasco Chemical Group, Inc.). Antigen
was retrieved using 0.05 M Glycine-HCL buffer, pH 3.5,
containing 0.01% (w/v) EDTA, at 95°C for 20 min and
stained with an antibody against human E-cadherin
(1:500), Keratin-18 (1:500) and Vimentin (1:500). Staining
was visualized with diaminobenzadine using the Cell and
Tissue Staining kit (R&D Systems). The immunostaining
was scored as positive or negative for E-cadherin, Kera-
tin-18 and Vimentin by a pathologist experienced in
immunohistochemistry of human tissue sections.
Statistics
Comparisons of cell density, number of colonies, invasion
index, relative levels of mRNA expression, the width of
the scratch wounds and relative levels of protein expres-
sion between the different transfections were conducted
using Student's t test. For tumor growth experiments,
repeated-measures ANOVA was used to examine the dif-
ferences in tumor sizes among different transfections,
time points, and transfection-time interactions. Addi-
tional post-test was done to examine the differences in
tumor sizes between vector control and other transfec-
tions at each time point by using conservative Bonferroni
method. All statistical tests were two sided. P < 0.05 was
considered statistically significant.
Results
The absence of WIF1 mRNA expression in the majority of 
PCa cell lines is associated with WIF1 promoter 
hypermethylation
WIF1 mRNA and protein expression was reported to be
down-regulated in PCa tissues [26]. However, the mecha-
nism of WIF1 down-regulation in PCa cells per se has not
b e e n  r e p o r t e d  y e t .  W e  s h o w  h e r e  t h a t  W I F 1  m R N A
expression is absent in the majority of PCa cell lines, as
well as in normal prostate epithelial cells (Figure 1A
&1B). Only 22Rv1 cell line has strong WIF1 mRNA
expression (Figure 1A &1B). In addition, Figure 1C shows
that all PCa cell lines and normal prostate epithelial cells
with loss of WIF1 expression exhibit a strong methylation
status in its promoter, whereas the promoter methylation
of WIF1 in 22Rv1 cell line was not detected (Figure 1C).
Furthermore, treatment of PC-3 cells with 1 μM 5-azacy-
tidine for 72 hours induced the re-expression of WIF1
mRNA (Figure 1D). Together, these results suggest that
the absence of WIF1 mRNA expression in the majority of
PCa cell lines is due to WIF1 promoter hypermethylation.Yee et al. Molecular Cancer 2010, 9:162
http://www.molecular-cancer.com/content/9/1/162
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WIF1 inhibits the canonical Wnt pathway
Bone metastases occur in approximately 70% of patients
with advanced PCa [34]. Since PC3 cell line was derived
from a bone metastatic PCa specimen, this cell line was
selected for further analysis of WIF1 mediated Wnt sig-
naling blockade. We confirmed the protein expression of
the WIF1 transgene tagged by V5 in stable PC3 cell line
by Western blot analysis using an anti-V5 antibody (Fig-
ure 2A). Figure 2A also shows that WIF1 expression
caused a decreased expression of both phospho-GSK3β
at serine-9 and -AKT at serine-473 without changing the
levels of their total protein. In addition, WIF1 expression
in PC3 cells decreased the protein levels of two common
Wnt target genes: Cycline D1 and c-Myc. Furthermore, to
examine the inhibition of canonical Wnt activity by
WIF1, LEF-1/TCF transcriptional activity was assessed
Figure 1 The loss of WIF1 expression in the majority of human PCa cell lines is associated with its promoter hypermethylation. A&B, the 
expression of WIF1 mRNA in eight PCa cell lines (LNCaP, LAPC4, 22Rv1, PC3, DU145, C4-2B, PC3 M, PC3-LN4) and PrEC were detected by regular RT-
PCR and quantified by real-time RT-PCR. Experiments were replicated thrice. C, WIF1 promoter hypermethylation is evident in seven of eight PCa cell 
lines. The methylation status of WIF-1 promoter was determined by the disulfite treatment of cell lines followed by methylation-specific PCR; M, meth-
ylation-specific primers; UM, unmethylation-specific primers. D, WIF1 expression in PC3 was reactivated by a demethylation agent 5-Aza-dC. After PC3 
cells were treated with 5-Aza-dC (5 μmol/L) for 72 h, RT-PCR was done to detect the WIF1 mRNA expression.
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Figure 2 Ectopic expression of WIF1 in PC3 cells inhibits AKT and GSK-3β, phosphorylation and LEF1/TCF transcriptional activity, leading 
to down-regulation of the expression of Wnt target genes: cyclin D1 and c-Myc. A, Western blot analysis of expression of WIF1, phospho-AKT, 
total AKT, Phospho-GSK-3β, total GSK-3β, cyclin D1 and c-Myc was shown by a representative blot from three independent experiments. B, WIF1 trans-
fection reduced TCF4 transcriptional activity in PC3 cells compared with vector control-transfected cells, measured by the TOPFLASH reporter assay 
and adjusted by transfection efficiency.
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b y  T O P F LAS H  l u c i f e r a s e  r e p o r t e r  a s s a y  i n  v e c t o r  a n d
WIF1 transfected PC3 cell lines. Adjustment of transfec-
tion efficiency was performed by co-transfection of a β-
galactosidase expression vector. Compared to controls,
WIF1 reduced LEF-1/TCF transcriptional activity by
approximately 56% (Figure. 2B, Student's t test; P < 0.05).
Together, these results indicate WIF1 expression inhibits
canonical Wnt activity in PC3 cells.
WIF1 expression induces a morphological transformation 
of PC3 cell from a fibroblastic to an epithelial appearance 
via up-regulation of epithelial markers and down-
regulation of mesenchymal markers in PC3 cells
When cell morphology was examined, PC3 cells express-
ing WIF1 were more compact and adherent to adjacent
cells than PC3 cells expressing PcDNA3.1, as seen in Fig-
ure 3A. This change to a more "adhesive" cellular mor-
phology resembles a transition from a fibroblastic to an
epithelial appearance. Furthermore, Figure 3B shows that
PC3 cells transfected with WIF1 but not those trans-
fected with PcDNA3.1 vector control exhibit intense
staining of E-cadherin along the entire cell-cell contact
region among neighboring cells and weaker staining in
the contact-free borders.
Consistent with the changes in morphology, ectopic
expression of WIF1 in PC3 cells results in a dramatic
increase in the protein levels of E-cadherin and keratin-8
and a decrease in N-cadherin, vimentin, and fibronectin
(Figure 3C). Together, these results suggest that WIF1
expression causes a reversal of EMT.
The modulation of EMT markers by WIF1 expression is 
associated with down-regulation of Slug/Twist expression 
in PC3 cells
Compared to vector control (PcDNA3.1) expression, real-
time PCR analysis also shows that WIF1 expression in
PC3 cells causes about 12 fold up-regulation of E-cad-
herin (P < 0.01), and leads to down-regulation of N-cad-
herin and Vimentin mRNA expression by 60% and 87%,
respectively (Ps < 0.05 and 0.01, respectively) (Figure 4A).
This result suggests that the effect of WIF1 on the expres-
sion of epithelial and mesenchymal markers in PC3 cells
may be associated with transcriptional regulation.
Embroynic transcriptional factors including Slug, Snail,
and Twist are master regulators of EMT and repressors
for E-cadherin gene transcription [35]. In addition, Wnt
signaling has been reported to cause up-regulation of the
expression of Slug and Twist [36,37]. Figure 4B shows
that inhibition of Wnt signaling by WIF1 expression
m a r k ed l y  d ecr eas es  t h e  m RN A  e x p r e s s i o n  o f  S l u g  a n d
Twist by about 99.9% and 93%, respectively (Ps < 0.01).
Consistently, Figure 4C demonstrates that the protein
levels of Slug and Twist are also decreased by WIF1
expression. Taken together, our results suggest that the
WIF1 induced reversal of EMT in PC3 cells is associated
with inhibition of Wnt signaling leading to down-regula-
tion of transcriptional factors Slug/Twist and up-regula-
tion of E-cadherin.
WIF1 suppresses cellular motility, and decreases the 
invasive capacity of PC3 cells via down-regulation of matrix 
metalloproteinase-2 and -9 activities
Based on the effects of WIF1 on EMT reversal, we next
examined the effect of WIF1 expression on migration of
PC3 cells using a wound healing assay. Figures 5A shows
that WIF1 transfected PC3 cells exhibited about 5.5 fold
slower migration into the wounded area, measured by
width of the gap, when compared with vector control
PcDNA3.1 transfected PC3 cells (P < 0.01).
We also examined the in vitro invasiveness of PC3 cells
expressing WIF1, or vector control in a Matrigel invasion
assay. The capacity of these cells to invade through a
Matrigel-coated membrane was expressed as average
number of migrated cells on the lower surfaces of tripli-
cate membranes and adjusted by cell motility. Cell motil-
ity was measured by average number of cells migrating
through a control, uncoated insert. Number of cells on
each membrane was averaged from 10 fields (×100).
WIF1-transfected cells exhibited a significant decrease in
invasive capacity (by 49%) compared with control cells
(Student's t test, P < 0.05; Figure. 5B).
MMP-2 and -9 play an important role in cell-matrix
interaction and tumor invasion in PCa [38] and Wnt sig-
naling has been reported to regulate the expression of
MMPs [39,40]. We therefore examined the effect of WIF1
on MMP-2 and MMP-9 activities and expression.
Zymography shows that ectopic expression of WIF1 in
PC3 cells resulted in decreased activities of both MMP-2
(lower band) and MMP-9 (upper band) in conditioned
medium (Figure 5C). The decrease in MMP-2 and-9
activities was correlated with lower MMP-2 and MMP-9
protein levels (Figure 5D). MMP-2 and MMP-9 activities
were also quantified by densitometric analysis and
adjusted by total number of cells in each culture. Com-
pared with vector control transfectants, WIF1 transfec-
tants showed a decrease in MMP-2 and -9 activities by
87% and 51%, respectively (Figure. 5C; Student's t test, Ps
< 0.01).
WIF1 inhibits in vivo tumor growth of PC3 cells in a 
xenograft mouse model, induces the expression of E-
cadherin and karatin-18 and decreases the expression of 
Vimentin in tumor tissues
Figure 6A shows that the ectopic expression of WIF1 in
PC3 cells resulted in a significant decrease in the growth
rate of tumors compared to control (ANOVA, P < 0.01).
The wet tumor weights were 0.84 ± 0.256 g in the control
group and 0.314 ± 0.18 g in the WIF1- transfectantsYee et al. Molecular Cancer 2010, 9:162
http://www.molecular-cancer.com/content/9/1/162
Page 8 of 14
Figure 3 Ectopic expression of WIF1 in PC3 cells results in a morphology change from a fibroblastic to an epithelial appearance, accompa-
nied by up-regulating the expression of epithelial markers and down-regulating the expression of mesenchymal markers. A, representative 
photograph of transfected cells at 60% confluence was taken under an inverted phase-contrast light microscope at ×200 magnification. B, the trans-
fectants were stained with anti-E-cadherin and Alex 488-conjugated secondary antibodies. Representative photographs were taken under a confocal 
microscope (Zeiss) at ×400 magnification. C, Western blot analysis of expression of E-cadherin, keratin-8, keratin-18, N-cadherin, vimentin, fibronectin, 
and β-actin shown by a representative blot from three independent experiments.
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Figure 4 The modulation of E-cadherin, N-cadherin, and vimentin mRNA levels by WIF1 transfection is associated with its down-regulation 
of Slug, and Twist expression. A & B, quantitative real-time PCR analysis of E-cadherin, N-cadherin, vimentin, Slug, and Twist mRNA in the transfec-
tants. Gene expression is presented as fold increase in Δ Ct compared with PCDNA3.1 vector control transfectants. Columns, mean of four independent 
quantitative real-time PCR experiments; Bars, ± SE. C, Western blot analysis of expression of Slug, Twist, and β-actin shown by a representative blot 
from three independent experiments.
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Figure 5 Ectopic expression of WIF1 in PC3 cells results in a reduction of cell migratory and invasive capacity and a decrease in MMP-2 and-
9 expression and activities. A, representative photomicrographs of scratch wounds at 0 and 30 h after wounds were made. Quantitative measure-
ment of wound gaps by Photoshop software showed a reduced cellular motility in the WIF1-transfected PC3 cells compared with vector control cells. 
Columns, mean fold changes of wound width in WIF1 versus vector control-transfected PC3 cells; bars, SD. Experiments were replicated thrice. B, cells 
were applied to the upper surface of a Matrigel-coated membrane. After incubation for 48 hours, the upper surface of the membrane was scrubbed 
free of cells; the membrane was fixed, stained, and photographed. Representative pictures were taken from the lower surface of four independent 
membranes at ×100 magnification. Invasion index was calculated by adjusting cellular motility as described in detail in Materials and Methods. Col-
umns, mean of invasion index calculated from four independent membranes; bars, SE. C, MMP-2 and MMP-9 activities in the conditioned medium 
from the transfectants were assayed by zymography as described in Materials and Methods. Semiquantitative comparison of MMP activities between 
PCDNA3.1 vector control and WIF1-transfected cells was done by densitometry. Columns, mean from three independent experiments; bars, SE. D, 
Western blot analysis of MMP-2 and MMP-9 expression. Representative blots were from three independent experiments. β-Actin serves as loading 
control.
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Figure 6 Ectopic expression of WIF1 in PC3 cells inhibits tumor growth in a xenograft model. PC3 cells (2 × 106) stably transfected with vector 
control or WIF1 were injected into the left flank of NCR-nu/nu (nude) mice. A, points, mean tumor volume (each group contains 13 mice); Bars, SD. B, 
at the termination of the study on day 48, tumors were excised from each mouse in different groups and weighed. Wet weight of tumors is represent-
ed as means of 13 tumors from individual mouse in each group. P < 0.05 at the termination of the experiments; Bars, ± SD. C, Immunohistochemical 
staining of ectopic E-cadherin, Keratin-18 and vimentin expression in harvested mouse tumor samples.
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group (Figure 6B; n = 13, mean ± SD; P < 0.05, Student's t
test). Ectopic WIF1 expression attenuated tumor growth
by approximately 63%.
Immunohistochemical analysis shows that tumor sec-
tions from the WIF1 transfected PC3 cell line exhibited a
marked increase in E-cadherin and Keratin-18 while
tumor sections from vector control cell line revealed no
or very weak staining (Figure 6C). In contrast, the density
of Vimentin staining was significantly decreased in the
WIF1 tumors compared to control tumors (Figure 6C).
Discussion
Bone metastases occur in approximately 70% of patients
with advanced PCa, causing severe morbidity and hospi-
talization [34]. WIF1 has been shown to play an impor-
tant functional role in the development of prostate and
bone [28-31]. Thus, the loss or down-regulation of WIF1
expression in PCa may have pathophysiological conse-
quences and, therefore, contribute to PCa development
and its metastasis to bone. Although WIF1 has been
shown to act as a tumor suppressor, inhibiting cancer cell
proliferation in many cancers [17-27], little is known
about its potential effect on metastatic tumors and the
process of tumor metastasis. We reported here that WIF1
promoter was hypermethylated in the majority of PCa
cell lines, leading to the absence of WIF1 mRNA expres-
sion in these cell lines. Re-expression of WIF1 in a bone
metastatic PCa cell line, PC3, resulted in an in vivo inhi-
bition of tumor growth and a decreased capacity of cell
migration and invasion. This suggests that the loss of
WIF1 in PCa may contribute to its metastatic potential.
WIF1's mechanism of action is associated with a reversal
of EMT process via  down-regulation of E-cadherin
expression, up-regulation of N-cadherin expression, and
decreased activity of MMP-2 and -9.
The EMT process was initially described in the context
of embryonic development and has recently been thought
to regulate invasive behavior of epithelial cancer cells at
the tumor-stromal interface [35]. EMT is characterized
by increased migratory features, decreased epithelial cell
adhesion, loss of cytoskeleton components and acquisi-
tion of mesenchymal components [35]. A hallmark of
EMT is the loss of E-cadherin expression [35]. Embryonic
transcription factors (The Slug/Snail, Ets, and Twist) are
transcriptional repressors of E-cadherin and the converg-
ing points for EMT-related pathways [35]. At present,
there are a very few reports that agents can reverse EMT
process in metastatic cancer cells. W e showed that re-
expression of WIF1 in PC3 cells changed cell morphology
from spindle-shaped to a cobblestone-like monolayer,
increased expression of epithelial markers (i.e. E-Cad-
herin and Keratin-8 and -18) and decreased expression of
mesenchymal markers (i.e. N-cadherin and Vimentin)
both in vitro cell cultures and in in vivo tumor tissues.
The increased expression of E-cadherin in the PC3 cell
with over-expression of WIF1 was associated with down-
regulation of the mRNA and protein levels of two tran-
scriptional repressors: Slug and Twist. Similarly, in a
recent study Xie et al [41] demonstrated that in meta-
static PCa cells restoring the expression of Disabled
homolog 2 interacting protein (DAB2IP), a Ras GTPase-
acting protein, leads to a reversal of EMT by interacting
with PP2A and GSK-3β and decreasing nuclear β-catenin
accumulation and its transcriptional activity. In an induc-
ible FGFR1 prostate mouse model that exhibited a highly
synchronous, step-wise progression to adenocarcinoma,
Acevedo et al [42] reported that the increase in Frizzled-4
r e c e p t o r  l e v e l s  a n d  t h e  d e c r e a s e  i n  W I F 1  l e v e l s  w e r e
related to EMT mediated cancer progression. In addition,
we have shown that ectopic expression of a dominant-
negative LRP5 in PC3 cells reversed EMT [32]. Taken
together, given LRP5 is a co-receptor of Frizzled-4 recep-
tor [43], these studies suggest that the Frizzled-4/LRP5
mediated β-catenin/TCF4 pathway may participate in
regulation of the EMT process in PCa progression and
that WIF1 may interfere with Wnts/Frizzled-4 or LRP5
interaction leading to a reversal of EMT. Therefore, fur-
ther studies are in progress to determine which Wnts or
Frizzled-4 ligands WIF1 could bind to in order to inhibit
the interaction between Frizzled/LRP5 and to reverse
EMT.
The antiproliferation effect of WIF1 has been consis-
tently reported in a wide variety of other cancer cell lines
[17-26]. In prostate cancer, Ohigashi et al [27] reported
that WIF1 overexpression only enhanced Paclitaxel-
induced apoptosis in PC3 Cells. However, we were unable
to detect any significant changes in cell proliferation and
apoptosis by WIF1 overexpression alone in PC3 cells
(data not shown). It is possible that the selection process
of establishing stable clones may attenuate the antiprolif-
erative effect of WIF1. However, we did show that WIF1
overexpression significantly inhibits in vivo tumor growth
of PC3 cells in a xenograft model. Thus, it is reasonable to
speculate that WIF1 may have an anti-angiogenesis effect
on tumor growth. Hu et al [44] recently reported that the
inhibition of tumor growth by adenoviral delivery of
WIF1-human IgG1 Fc fragment fusion protein in hepato-
cellular carcinoma mouse xenograft models is associated
with reduced microvessel density, decreased expression
of vascular endothelial growth factor, decreased stromal
cell-derived factor-1 and increased apoptosis. Emerging
evidence also suggest that Wnt signaling plays an impor-
tant role in vascular development [45]. However, the
potential effects and mechanism of WIF1 on angiogene-
sis are largely unexplored. Therefore, it is important to
study whether WIF1 will have an anti-angiogenesis effect
on PCa. It is also important to understand the potential
molecular mechanisms of WIF1's effect on angiogenesis.Yee et al. Molecular Cancer 2010, 9:162
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Conclusions
T h e  f r e q u e n t  a b s e n c e  o f  W I F 1  e x p r e s s i o n  i n  P C a  c e l l
lines is associated with its promoter hypermethylation.
Restoring WIF1 expression in WIF1 deficient PCa cells
resulted in a decreased cellular capacity of migration and
invasion, which was associated with a reversal of EMT. In
addition, WIF1 restoration inhibited the in vivo growth of
PCa cancer cells in a xenograft model. Together, these
results suggest that the potential of WIF1 as an anti- inva-
siveness agent alone or in combination with other agents
deserves further study in the treatment of castration-
resistant PCa.
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